Adela: Lisa Alderson
Minimal residual monitoring and early cancer detection firm Adela has appointed Lisa Alderson its CEO following a nationwide search. She has been the Foster City, California-based company's interim CEO since the middle of 2023 and has been on its board since 2022. Alderson previously founded Genome Medical where she was also its CEO. She also was Invitae's chief commercial officer and chief strategy officer and was part of the startup team at Genomic Health. Adela leverages a proprietary genome-wide methylome enrichment technology and plans to commercialize its first product, a tissue-agnostic test for MRD monitoring, in 2025.